The University of California San Diego’s incoming Alzheimer’s research czar talked with Alzforum about where he wants to take the embattled Alzheimer’s Disease Cooperative Study and neurodegeneration research in the region.
Correctly diagnosing Alzheimer’s disease remains a challenge for medical professionals. Now, a new study published in the current issue of the Journal of Alzheimer’s Disease reveals a new clue to possible misdiagnosis.
A Mayo Clinic study of people who received anesthesia for surgery after age 40 found no association between the anesthesia and development of mild cognitive impairment later in life.
Alzheimer’s disease relentlessly targets large-scale brain networks that support the formation of new memories. However, it remains a mystery as to why the disease selectively targets memory-related brain networks and how this relates to misfolded proteins seen by pathologists at autopsy.
Howard Feldman, MD, FRCP(C), a renowned Canadian neurologist noted for his original research in geriatric cognitive disorders and expertise in large-scale clinical trials, has been named the new director of the Alzheimer’s Disease Cooperative Study (ADCS) at University of California, San Diego, pending approval from the National Institute on Aging (NIA).
A new study from the Monell Center, the U.S. Department of Agriculture, and collaborating institutions reports a uniquely identifiable odor signature from mouse models of Alzheimer’s disease. The findings suggest that it may be possible to develop a non-invasive tool for early Alzheimer’s diagnosis.
/PRNewswire-USNewswire/ -- PsychoGenics Inc. and the Alzheimer's Drug Discovery Foundation (ADDF) announce a new partnership to bring PsychoGenics' validated Alzheimer's animal models and experimental services to ADDF grantees working on preclinical Alzheimer's drug discovery programs. Through the partnership, PsychoGenics will establish risk-sharing agreements with ADDF-funded biotechnology companies to make its services available under extremely favorable financial terms, thus increasing the value of the ADDF's grants.
In atherosclerosis, plaque builds up on the inner walls of arteries that deliver blood to the body. Studying mice and tissue samples from the arteries of patients, researchers at Washington University School of Medicine in St. Louis suggest this accumulation is driven, at least in part, by processes similar to the plaque formation implicated in brain diseases such as Alzheimer’s and Parkinson’s.
A University of Southampton-led study has found that blocking a receptor in the brain responsible for regulating immune cells could protect against the memory and behaviour changes seen in the progression of Alzheimer’s disease.
A diet proven to lower the risk of Alzheimer's disease by as much as 53 percent in participants who adhered to the diet rigorously has also been ranked as the easiest diet to follow by U.S. News & World Report.
Researchers at the laboratory for research of molecular and cellular mechanisms underlying learning and memory, directed by Prof. Kobi Rosenblum, found that “repairing” the activity led to an improvement in memory. A start-up they established on the basis of the findings will attempt to develop drugs delaying the onset of cognitive symptoms
Two genetic variants previously linked to Alzheimer's disease have been more specifically tied to brain atrophy that is characteristic of the disease, and could be the basis for future blood biomarker tests.
The most complicated of the age-relating dementing diseases just got a little clearer. Marked by degeneration of both the mind and the body, dementia with Lewy bodies combines aspects of both Alzheimer’s and Parkinson’s. DLB has for years languished in the shadows of its eponymous cousins when it came to recognition and research funding, but a recent, once-in-a-decade international conference showcased progress in better defining what DLB is and setting the stage for therapy trials.
A drug that boosts activity in the brain’s “garbage disposal” system can decrease levels of toxic proteins associated with Alzheimer’s disease and other neurodegenerative disorders and improve cognition in mice, a new study by neuroscientists at Columbia University Medical Center (CUMC) has found.
The holidays are a time when families get together -- sometimes after long periods apart. How can you tell if Grandma is aging normally, or is perhaps showing signs of serious mental decline? Look for these early signs of dementia in an elderly loved one.
Feeling stressed out increases the likelihood that elderly people will develop mild cognitive impairment—often a prelude to full-blown Alzheimer’s disease. In a new study, scientists at Albert Einstein College of Medicine and Montefiore Health System found that highly stressed participants were more than twice as likely to become impaired than those who were not. Because stress is treatable, the results suggest that detecting and treating stress in older people might help delay or even prevent the onset of Alzheimer’s. The findings were published online today in Alzheimer Disease & Associated Disorders.
Researchers have discovered how to diagnose Alzheimer’s disease with more than 82 per cent accuracy by evaluating the interplay between four linguistic factors; and developing automated technology to detect these impairments.
UAB researchers have found that, contrary to current thinking, astrocytes are repelled by the amyloid plaques that are linked to the disease. pplying mathematical models used for studying the galaxies or interactions between elementary particles, researchers at the Institute of Neuroscience of the Universitat Autònoma de Barcelona, in collaboration with Massachusetts General Hospital, Boston, have analysed the spatial distribution of astrocytes: brain cells that are essential for the correct functioning of neurons.
In a quest to stay healthy, many people are seeking natural ways to prevent neurodegenerative diseases. Recent studies show that pomegranate extract, which is a rich source of disease-fighting polyphenols, can help protect against the development of Alzheimer's disease. But researchers weren't sure which molecules to thank. A team reports in ACS Chemical Neuroscience that the responsible compounds may be urolithins, which are made when gut bacteria break down the polyphenols in the extract.
Scientists have made several kinds of mice in the hope of mimicking ALS and frontotemporal dementia, diseases caused by mutations in the C9ORF72 gene. Early results indicate that the mutated genes generate unusual RNAs and proteins, but that losing the normal C9ORF72 gene does not kill neurons.
How fast elderly people walk may be related to the amount of amyloid they have built up in their brains, even if they don’t yet have symptoms of Alzheimer’s disease, according to a study published in the December 2, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology.
NYU Langone Medical Center has been awarded a five-year $7.5 million grant to provide caregivers for individuals with Alzheimer’s disease and other dementias with access to state-of-the-art support programs and services designed to improve quality of life.
New York State Governor Andrew M. Cuomo announced in November that $67.6 million has been awarded to nine organizations across the state as part of his Alzheimer's Caregiver Support Initiative to develop programs that support family members and caregivers for New Yorkers living with Alzheimer’s and dementia.
In addition to treating depression, a commonly used antidepressant medication also protects against compounds that can cause memory loss and dementia, a Loyola University Medical Center study has found.
A University of California, Irvine research team is part of a $37 million national effort to identify biomarkers that will predict the onset of Alzheimer’s disease in people with Down syndrome. UCI pediatric neurologist Dr. Ira Lott and colleagues will receive $4.7 million of that funding from the National Institute on Aging to support his continuing work to uncover the mystery of progressive cognitive impairment seen in some people over 40 with Down syndrome.
Lewy body dementia is the second most common type of dementia after Alzheimer’s disease. But if you’re not familiar with it, you’re not alone. “Lewy body dementia is the most common disorder you’ve never heard of,” says Bradley Boeve, M.D., a Mayo Clinic neurologist who will speak at the International Dementia with Lewy Bodies Conference Dec. 1-4 in Fort Lauderdale, Florida.
Amyloid beta, the plaque that accumulates in the brains of people with Alzheimer’s disease, may also contribute to Alzheimer’s by interfering with normal blood flow in the brain, according to investigators UAB.
In findings published Nov. 23 in the journal Brain, the team shows that when amyloid beta accumulates around blood vessels — where it is known as vascular amyloid — it appears to prevent the brain from properly regulating blood flow, which is essential to normal brain function.
Virginia Tech Carilion Research Institute scientists have uncovered a mechanism in the brain that could account for some of the neural degeneration and memory loss in people with Alzheimer’s disease.
The researchers, together with scientists at the University of Alabama at Birmingham School of Medicine, discovered that a common symptom of Alzheimer’s disease – the accumulation of amyloid plaques along blood vessels – could be disrupting blood flow in the brain.
Older adults who take college courses may increase their cognitive capacity and possibly reduce their risk for developing Alzheimer’s disease or other forms of dementia, according to new research published by the American Psychological Association.
In a novel animal study design that mimicked human clinical trials, researchers at University of California, San Diego School of Medicine report that long-term treatment using a small molecule drug that reduces activity of the brain’s stress circuitry significantly reduces Alzheimer’s disease (AD) neuropathology and prevents onset of cognitive impairment in a mouse model of the neurodegenerative condition. The findings are described in the current online issue of the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
Mayo Clinic’s Florida campus was awarded a $5.3 million grant from the National Institutes of Health (NIH) to identify vascular risk factors in aging and dementia, and translate that knowledge into studying potential targets for treatment.
More than five million Americans and 15 million caregivers are impacted by Alzheimer's disease. A leading neuroscientist at Florida Atlantic University has developed eight myths and truths about this prevalent form of dementia.
Principal Investigator Takes Questions and Demonstrates Procedure with Video and Animation via Virtual Press Conference Tuesday, November 10th at 1:00 p.m. ET
Researchers from the University of Southampton have discovered a possible solution for side effects seen in immunotherapy treatment for Alzheimer’s disease.
The late Robin Williams had this form of dementia, which also can cause visual hallucinations and make depression worse. Until now, there has been no way to assess or operationalize many of the cognitive and behavioral symptoms of Lewy Body dementia in clinical practice.
An estrogen-like drug, raloxifene, has no demonstrated benefit on memory and thinking skills for women with dementia due to Alzheimer’s disease, according to a study published in the November 4, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Yesterday, Susan Williams, Robin Williams’ widow, spoke on Good Morning America (GMA) and in other media, about it taking the past year for her to learn that Robin was suffering from Lewy body dementia (LBD), which she believes led him to take his own life. Susan Williams explained that the original Parkinson’s diagnosis did not cover all of his symptoms, and he was unaware of the LBD diagnosis when he died.
Driving simulation and real-world data recording systems will shed light on brain health, functional abilities of people with neurological problems neurological disorders
New research suggests that older women who complain of memory problems may be at higher risk for experiencing diagnosed memory and thinking impairment decades later. The study is published in the October 28, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Chemical changes in brain cells caused by disturbances in the body’s day-night cycle may be a key underlying cause of the learning and memory loss associated with Alzheimer’s disease, according to a University of California, Irvine study.
The cost of care over the last five years of life for patients with dementia is significantly higher than for patients who die from heart disease, cancer, or other causes, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai, Dartmouth College and University of California, Los Angeles, and published online today in the journal Annals of Internal Medicine.
Although Lewy Body disease (LBD) is the second-most-common degenerative disease after Alzheimer’s disease (AD), it’s not exactly a household name. A fast, new test can assess clinical signs and symptoms of this disease, and discriminate between AD and LBD with 96
Using 10-year-old archival brain tissue from patients with Alzheimer’s disease, a research team from NYU Langone Medical Center has developed a novel method to examine the structure and function of proteins at the cell level -- providing greater means to study protein changes found in Alzheimer’s disease.